

Anderson J. Ryan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/594281/publications.pdf>

Version: 2024-02-01

133
papers

7,854
citations

57631

44
h-index

56606

83
g-index

135
all docs

135
docs citations

135
times ranked

9793
citing authors

#	ARTICLE	IF	CITATIONS
1	CHK1 inhibition exacerbates replication stress induced by IGF blockade. <i>Oncogene</i> , 2022, 41, 476-488.	2.6	4
2	Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours. <i>EMBO Molecular Medicine</i> , 2022, 14, e14501.	3.3	13
3	Targeting TOPK sensitises tumour cells to radiation-induced damage by enhancing replication stress. <i>Cell Death and Differentiation</i> , 2021, 28, 1333-1346.	5.0	13
4	Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction. <i>Cancer Research</i> , 2021, 81, 2128-2141.	0.4	10
5	Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response. <i>Cancer Research</i> , 2021, 81, 1667-1680.	0.4	32
6	Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model. <i>British Journal of Cancer</i> , 2021, 124, 1809-1819.	2.9	5
7	Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus. <i>Molecular Therapy</i> , 2021, 29, 1668-1682.	3.7	33
8	DNAPK Inhibition Preferentially Compromises the Repair of Radiation-induced DNA Double-strand Breaks in Chronically Hypoxic Tumor Cells in Xenograft Models. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1663-1671.	1.9	5
9	CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2020, 25, 61-66.	0.9	15
10	Adefovir dipivoxil induces DNA replication stress and augments ATR inhibitor-related cytotoxicity. <i>International Journal of Cancer</i> , 2020, 147, 1474-1484.	2.3	7
11	Identification of anticancer drugs to radiosensitize BRAF-wild-type and mutant colorectal cancer. <i>Cancer Biology and Medicine</i> , 2019, 16, 234.	1.4	4
12	Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer. <i>BMC Cancer</i> , 2019, 19, 102.	1.1	29
13	Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance. <i>EMBO Molecular Medicine</i> , 2019, 11, e9982.	3.3	26
14	RASSF1A controls tissue stiffness and cancer stem-like cells in lung adenocarcinoma. <i>EMBO Journal</i> , 2019, 38, e100532.	3.5	83
15	Cardio-Respiratory synchronized bSSFP MRI for high throughput in vivo lung tumour quantification. <i>PLoS ONE</i> , 2019, 14, e0212172.	1.1	7
16	Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy. <i>Journal of Clinical Investigation</i> , 2019, 130, 258-271.	3.9	45
17	PARP Inhibition Combined With Thoracic Irradiation Exacerbates Esophageal and Skin Toxicity in C57BL6 Mice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 767-775.	0.4	22
18	Pre-clinical Profile and Expectations for Pharmacological ATM Inhibition. <i>Cancer Drug Discovery and Development</i> , 2018, , 155-183.	0.2	0

#	ARTICLE	IF	CITATIONS
19	Persistent DNA strand breaks induce a CAF-like phenotype in normal fibroblasts. <i>Oncotarget</i> , 2018, 9, 13666-13681.	0.8	20
20	The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5489-5501.	3.2	55
21	BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity. <i>EMBO Molecular Medicine</i> , 2017, 9, 1398-1414.	3.3	57
22	TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy. <i>British Journal of Cancer</i> , 2017, 117, 503-512.	2.9	20
23	Abstract B30: Novel targets for combination therapy in EGFR mutated NSCLC. , 2017, , .		0
24	Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 60807-60822.	0.8	23
25	Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 772-781.	0.4	39
26	Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds. <i>Molecular Cell</i> , 2016, 61, 449-460.	4.5	185
27	Abstract B40: WEE1 inhibition selectively kills histone H3K36me3-deficient cancers by dNTP starvation. , 2016, , .		0
28	Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer. <i>International Journal of Oncology</i> , 2015, 47, 849-856.	1.4	29
29	Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation. <i>Cancer Cell</i> , 2015, 28, 557-568.	7.7	244
30	Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture. <i>Lung Cancer</i> , 2015, 90, 191-198.	0.9	14
31	ATM and ATR as therapeutic targets in cancer. , 2015, 149, 124-138.		487
32	EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer. <i>Annals of Oncology</i> , 2014, 25, 1941-1948.	0.6	20
33	Changes in Signaling Pathways Induced by Vandetanib in a Human Medullary Thyroid Carcinoma Model, as Analyzed by Reverse Phase Protein Array. <i>Thyroid</i> , 2014, 24, 43-51.	2.4	8
34	Erlotinib, Gefitinib, and Vandetanib Inhibit Human Nucleoside Transporters and Protect Cancer Cells from Gemcitabine Cytotoxicity. <i>Clinical Cancer Research</i> , 2014, 20, 176-186.	3.2	37
35	Short-Course Treatment With Gefitinib Enhances Curative Potential of Radiation Therapy in a Mouse Model of Human Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 947-954.	0.4	26
36	Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells. <i>Oncotarget</i> , 2014, 5, 4765-4778.	0.8	42

#	ARTICLE	IF	CITATIONS
37	Abstract 3785: Olaparib increases the effectiveness of radiation in hypoxic tumor cells in xenograft models of human non-small-cell lung cancer. , 2014, , .		0
38	Replication Stress and Chromatin Context Link ATM Activation to a Role in DNA Replication. <i>Molecular Cell</i> , 2013, 52, 758-766.	4.5	102
39	An Integrated Inspection of the Somatic Mutations in a Lung Squamous Cell Carcinoma Using Next-Generation Sequencing. <i>PLoS ONE</i> , 2013, 8, e78823.	1.1	5
40	Abstract B91: Combined ATM and ATR kinase inhibition selectively kills p53-mutated non-small cell lung cancer (NSCLC) cells.. <i>Molecular Cancer Therapeutics</i> , 2013, 12, B91-B91.	1.9	3
41	Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model, as analyzed by Reverse Phase Protein Array.. <i>Thyroid</i> , 2013, , 130703231537001.	2.4	0
42	Abstract B276: A live-cell apoptosis assay identifies novel combination approaches that selectively kill EGFR mutant NSCLC cells.. , 2013, , .		0
43	Reply to J.-F. Chatal et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 2166-2167.	0.8	0
44	Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 134-141.	0.8	1,295
45	False-negative MRI biomarkers of tumour response to targeted cancer therapeutics. <i>British Journal of Cancer</i> , 2012, 106, 1960-1966.	2.9	10
46	Combined MEK and VEGFR Inhibition in Orthotopic Human Lung Cancer Models Results in Enhanced Inhibition of Tumor Angiogenesis, Growth, and Metastasis. <i>Clinical Cancer Research</i> , 2012, 18, 1641-1654.	3.2	51
47	Inhibition of Aurora-B kinase activity confers antitumor efficacy in preclinical mouse models of early and advanced gastrointestinal neoplasia. <i>International Journal of Oncology</i> , 2012, 41, 1475-1485.	1.4	10
48	Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas. <i>International Journal of Cancer</i> , 2012, 131, 1854-1862.	2.3	9
49	Antitumor effect of the vascular-disrupting agent ZD6126 in a murine renal cell carcinoma model. <i>International Journal of Oncology</i> , 2011, 38, 455-64.	1.4	3
50	Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer. <i>International Journal of Oncology</i> , 2011, 39, 271-8.	1.4	13
51	Investigating temporal fluctuations in tumor vasculature with combined carbogen and ultrasmall superparamagnetic iron oxide particle (CUSPIO) imaging. <i>Magnetic Resonance in Medicine</i> , 2011, 66, 227-234.	1.9	11
52	Abstract 5471: Pharmacokinetic investigation of vandetanib in patients with medullary thyroid carcinoma using liquid chromatography-tandem mass spectrometry. , 2011, , .		0
53	Abstract 3569: Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model as detected by reverse phase protein arrays. , 2011, , .		0
54	Abstract 629: MEK inhibition by selumetinib (AZD6244) inhibits progression with a multicentric antiangiogenic effect and enhances the efficacy of cediranib in orthotopic human lung cancer models. , 2011, , .		0

#	ARTICLE	IF	CITATIONS
55	Abstract 3279: Effects of the isoforms of the angiogenic growth factor VEGF on neo-vascularization and tumor response to the tyrosine kinase inhibitor cediranib. , 2011, , .		0
56	Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced ApcMIN/+ mouse model. International Journal of Oncology, 2010, 37, 767-72.	1.4	3
57	Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 193-201.	0.8	131
58	Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers. Clinical Cancer Research, 2010, 16, 3548-3561.	3.2	202
59	The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocrine-Related Cancer, 2010, 18, 1-11.	1.6	58
60	Assessment of Acute Antivascular Effects of Vandetanib with High-Resolution Dynamic Contrast-Enhanced Computed Tomographic Imaging in a Human Colon Tumor Xenograft Model in the Nude Rat. Neoplasia, 2010, 12, 697-707.	2.3	20
61	Circulating free DNA as a surrogate for tumor material for EGFR and KRAS analysis. , 2010, , .		1
62	The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues. British Journal of Cancer, 2009, 101, 418-423.	2.9	1
63	Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. Molecular Cancer Therapeutics, 2009, 8, 2546-2558.	1.9	40
64	Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non-Small Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 3600-3609.	3.2	90
65	Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474. Endocrine-Related Cancer, 2009, 16, 233-241.	1.6	37
66	Combination of Vandetanib, Radiotherapy, and Irinotecan in the LoVo Human Colorectal Cancer Xenograft Model. International Journal of Radiation Oncology Biology Physics, 2009, 75, 854-861.	0.4	13
67	DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. Journal of Angiogenesis Research, 2009, 1, 5.	2.9	47
68	The Effects of Vandetanib on Paclitaxel Tumor Distribution and Antitumor Activity in a Xenograft Model of Human Ovarian Carcinoma. Neoplasia, 2009, 11, 1155-1167.	2.3	31
69	Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma. Anticancer Research, 2009, 29, 5065-76.	0.5	15
70	Longitudinal in vivo susceptibility contrast MRI measurements of LS174T colorectal liver metastasis in nude mice. Journal of Magnetic Resonance Imaging, 2008, 28, 1451-1458.	1.9	19
71	Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma. British Journal of Cancer, 2008, 99, 1256-1264.	2.9	28
72	Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. Cancer Letters, 2008, 265, 55-66.	3.2	26

#	ARTICLE	IF	CITATIONS
73	Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in ApcMin/+ mice. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 590-598.	1.9	36
74	Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti-“Epidermal Growth Factor Receptor Drugs in Human Cancer Cells. <i>Clinical Cancer Research</i> , 2008, 14, 5069-5080.	3.2	139
75	Vandetanib Inhibits Growth of Adenoid Cystic Carcinoma in an Orthotopic Nude Mouse Model. <i>Clinical Cancer Research</i> , 2008, 14, 5081-5089.	3.2	23
76	Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 418-424.	1.9	47
77	Vandetanib (ZACTIMA®, ZD6474): Preclinical and Clinical Development. , 2008, , 741-759.		0
78	Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 471-483.	1.9	84
79	Distribution of radioactivity and metabolite profiling in tumour and plasma following intravenous administration of a colchicine derivative (14C-ZD6126) to tumour-bearing mice. <i>Xenobiotica</i> , 2007, 37, 328-340.	0.5	10
80	Effect of Pretreatment With Atenolol and Nifedipine on ZD6126-Induced Cardiac Toxicity in Rats. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1724-1728.	3.0	26
81	Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. <i>Anti-Cancer Drugs</i> , 2007, 18, 569-579.	0.7	28
82	Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 239-249.	1.9	131
83	Correlation of MRI Biomarkers with Tumor Necrosis in Hras5 Tumor Xenograft in Athymic Rats. <i>Neoplasia</i> , 2007, 9, 382-391.	2.3	32
84	A5-02: Targeted therapy against VEGFR and/or EGFR signaling with AZD2171, vandetanib, and gefitinib as part of a combined modality approach for the treatment of non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, S323.	0.5	0
85	Susceptibility Contrast Magnetic Resonance Imaging Determination of Fractional Tumor Blood Volume: A Noninvasive Imaging Biomarker of Response to the Vascular Disrupting Agent ZD6126. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 872-879.	0.4	26
86	Targeted Therapy Against VEGFR and EGFR With ZD6474 Enhances the Therapeutic Efficacy of Irradiation in an Orthotopic Model of Human Non-“Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1534-1543.	0.4	58
87	Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. <i>British Journal of Cancer</i> , 2007, 97, 888-894.	2.9	49
88	The Response of RIF-1 Fibrosarcomas to the Vascular-Disrupting Agent ZD6126 Assessed by In Vivo and Ex Vivo 1H Magnetic Resonance Spectroscopy. <i>Neoplasia</i> , 2006, 8, 560-567.	2.3	36
89	Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126. <i>Microvascular Research</i> , 2006, 71, 76-84.	1.1	32
90	ZD6474, an Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase, Inhibits Growth of Experimental Lung Metastasis and Production of Malignant Pleural Effusions in a Non-Small Cell Lung Cancer Model. <i>Oncology Research</i> , 2006, 16, 15-26.	0.6	45

#	ARTICLE	IF	CITATIONS
91	Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer. <i>Carcinogenesis</i> , 2006, 27, 2133-2139.	1.3	56
92	A Longitudinal Study of R2* and R2 Magnetic Resonance Imaging Relaxation Rate Measurements in Murine Liver After a Single Administration of 3 Different Iron Oxide-Based Contrast Agents. <i>Investigative Radiology</i> , 2005, 40, 784-791.	3.5	32
93	ZD6474 â€“ a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. <i>British Journal of Cancer</i> , 2005, 92, S6-S13.	2.9	160
94	ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors. <i>Clinical Cancer Research</i> , 2005, 11, 8145-8157.	3.2	94
95	Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity. <i>Clinical Cancer Research</i> , 2005, 11, 3514-3522.	3.2	145
96	Potential Antagonism of Tubulin-Binding Anticancer Agents in Combination Therapies. <i>Clinical Cancer Research</i> , 2005, 11, 2720-2726.	3.2	23
97	Antitumor Vascular Strategy for Controlling Experimental Metastatic Spread of Human Small-Cell Lung Cancer Cells with ZD6474 in Natural Killer Cellâ€“Depleted Severe Combined Immunodeficient Mice. <i>Clinical Cancer Research</i> , 2005, 11, 8789-8798.	3.2	45
98	ZD6474 Suppresses Oncogenic RET Isoforms in a Drosophila Model for Type 2 Multiple Endocrine Neoplasia Syndromes and Papillary Thyroid Carcinoma. <i>Cancer Research</i> , 2005, 65, 3538-3541.	0.4	133
99	Cooperative Antitumor Effect of Multitargeted Kinase Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma. <i>Clinical Cancer Research</i> , 2005, 11, 5639-5644.	3.2	83
100	Acute Tumor Response to ZD6126 Assessed by Intrinsic Susceptibility Magnetic Resonance Imaging. <i>Neoplasia</i> , 2005, 7, 466-474.	2.3	32
101	Vascular-Targeting Agents and Radiation Therapy in Lung Cancer: Where Do We Stand in 2005?. <i>Clinical Lung Cancer</i> , 2005, 7, 175-179.	1.1	6
102	Vascular Targeting in Pancreatic Cancer: The Novel Tubulin-Binding Agent ZD6126 Reveals Antitumor Activity in Primary and Metastatic Tumor Models. <i>Neoplasia</i> , 2005, 7, 957-966.	2.3	17
103	Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. <i>Clinical Cancer Research</i> , 2005, 11, 835-42.	3.2	84
104	Regulation of p27Kip1 Protein Levels Contributes to Mitogenic Effects of the RET/PTC Kinase in Thyroid Carcinoma Cells. <i>Cancer Research</i> , 2004, 64, 3823-3829.	0.4	45
105	Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126. <i>Clinical Cancer Research</i> , 2004, 10, 3650-3657.	3.2	162
106	Inhibition of Src Tyrosine Kinase as Treatment for Human Pancreatic Cancer Growing Orthotopically in Nude Mice. <i>Clinical Cancer Research</i> , 2004, 10, 8028-8036.	3.2	128
107	ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer. <i>British Journal of Cancer</i> , 2004, 90, 705-711.	2.9	21
108	Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. <i>Oncogene</i> , 2004, 23, 6056-6063.	2.6	227

#	ARTICLE	IF	CITATIONS
109	In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model. <i>Angiogenesis</i> , 2004, 7, 157-164.	3.7	22
110	The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. <i>Angiogenesis</i> , 2004, 7, 347-354.	3.7	36
111	Single Dose of the Antivasular Agent, ZD6126 (N-Acetylcoichinol-O-Phosphate), Reduces Perfusion for at Least 96 Hours in the GH3 Prolactinoma Rat Tumor Model. <i>Neoplasia</i> , 2004, 6, 150-157.	2.3	34
112	ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 1041-8.	1.9	75
113	Tumour dose response to the antivasular agent ZD6126 assessed by magnetic resonance imaging. <i>British Journal of Cancer</i> , 2003, 88, 1592-1597.	2.9	114
114	ZD6126: A novel small molecule vascular targeting agent. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 1497-1502.	0.4	66
115	Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. <i>Clinical Cancer Research</i> , 2002, 8, 1974-83.	3.2	135
116	ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. <i>Cancer Research</i> , 2002, 62, 7284-90.	0.4	463
117	Lack of correlation between residual radiation-induced DNA damage, in keratinocytes assayed directly from skin, and late radiotherapy reactions in breast cancer patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 43, 481-487.	0.4	16
118	A correlation between residual radiation-induced DNA double-strand breaks in cultured fibroblasts and late radiotherapy reactions in breast cancer patients. <i>Radiotherapy and Oncology</i> , 1999, 51, 55-65.	0.3	55
119	Targeting Double-Strand Breaks to Replicating DNA Identifies a Subpathway of DSB Repair That Is Defective in Ataxia-Telangiectasia Cells. <i>Biochemical and Biophysical Research Communications</i> , 1999, 261, 317-325.	1.0	53
120	SYBR Green I staining of pulsed field agarose gels is a sensitive and inexpensive way of quantitating DNA double-strand breaks in mammalian cells. <i>Nucleic Acids Research</i> , 1997, 25, 2945-2946.	6.5	47
121	A correlation between residual DNA double-strand breaks and clonogenic measurements of radiosensitivity in fibroblasts from preradiotherapy cervix cancer patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 39, 1137-1144.	0.4	36
122	Dominant genetic instability and sensitivity to DNA damaging agents in a mammalian cell line. <i>Somatic Cell and Molecular Genetics</i> , 1996, 22, 177-189.	0.7	1
123	Different fates of camptothecin-induced replication fork-associated double-strand DNA breaks in mammalian cells. <i>Carcinogenesis</i> , 1994, 15, 823-828.	1.3	47
124	Problems and paradigms: Fine tuning of DNA repair in transcribed genes: Mechanisms, prevalence and consequences. <i>BioEssays</i> , 1993, 15, 209-216.	1.2	26
125	Characterisation and correction of a mammalian cell mutant defective in late step of base excision repair. <i>Somatic Cell and Molecular Genetics</i> , 1992, 18, 529-541.	0.7	1
126	A class of amphipathic proteins associated with lipid storage bodies in plants. Possible similarities with animal serum apolipoproteins. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1991, 1088, 86-94.	2.4	70

#	ARTICLE	IF	CITATIONS
127	Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. <i>Nucleic Acids Research</i> , 1991, 19, 3295-3300.	6.5	211
128	Genomic sequence of a 12S seed storage protein from oilseed rape (<i>Brassica napus</i> c.v.jet neuf). <i>Nucleic Acids Research</i> , 1989, 17, 3584-3584.	6.5	23
129	Increased oncogene expression in livers of rats after exposure to dimethylnitrosamine. <i>Biochemical Society Transactions</i> , 1988, 16, 1058-1059.	1.6	4
130	Micrococcal nuclease digests intranucleosomal DNA of inactive genes more rapidly than active genes. <i>Biochemical Society Transactions</i> , 1988, 16, 1060-1061.	1.6	0
131	Highly selective binding of the carcinogen benzo[<i>a</i>]pyrene diol epoxide to nuclear matrix/scaffold DNA. <i>Biochemical Society Transactions</i> , 1986, 14, 1164-1165.	1.6	1
132	Selective repair of methylated purines in regions of chromatin DNA. <i>Carcinogenesis</i> , 1986, 7, 1497-1503.	1.3	43
133	Preferential binding of the carcinogen benzo[<i>a</i>]pyrene to DNA in active chromatin and the nuclear matrix. <i>Carcinogenesis</i> , 1986, 7, 907-913.	1.3	47